| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3419612 | Revue de Pneumologie Clinique | 2013 | 11 Pages |
Abstract
Bevacizumab (Avastin®) is the first antiangiogenic therapy approved in non-small cell lung cancer (NSCLC). It is also currently the only agent in this family approved in NSCLC. This review focuses on results of clinical trials assessing bevacizumab in thoracic oncology. It also provides to clinicians practical advices for its prescription.
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
Ã. Dansin, S. Cousin, G. Lauridant, B. Mennecier,